Literature DB >> 17141853

Guideline-defining asthma clinical trials of the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research and Education Network.

Loren C Denlinger1, Christine A Sorkness, Vernon M Chinchilli, Robert F Lemanske.   

Abstract

Because of an increasing prevalence, morbidity, and mortality associated with asthma, the National Heart, Lung, and Blood Institute created the Asthma Clinical Research Network and the Childhood Asthma Research and Education Network to improve public health. The objectives of these clinical research networks are to conduct multiple, well-designed clinical trials for rapid evaluation of new and existing therapeutic approaches to asthma and to disseminate laboratory and clinical findings to the health care community. These trials comprise a large proportion of the data driving the treatment guidelines established and reviewed by the National Asthma Education and Prevention Program. This article will review the basic design and major findings of selected Asthma Clinical Research Network and Childhood Asthma Research and Education Network trials involving both adults and children with asthma. Collectively, these studies have helped refine the therapeutic role of existing controller medications, establish standard models for side-effect evaluation and risk-benefit models, validate symptom-based assessments for asthma control, and identify baseline characteristics that might predict individual patient responses. Remaining challenges include shaping the role of novel therapeutics in future guidelines, incorporating pharmacogenomic data in treatment decisions, and establishing better implementation strategies for translation to community settings, all with the goal of reducing the asthma burden on society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17141853      PMCID: PMC2742212          DOI: 10.1016/j.jaci.2006.10.015

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  43 in total

1.  Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma.

Authors:  J A van Noord; A J Schreurs; S J Mol; P G Mulder
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

Review 2.  Influence of inhaled corticosteroids on growth: a pediatric endocrinologist's perspective.

Authors:  D B Allen
Journal:  Acta Paediatr       Date:  1998-02       Impact factor: 2.299

3.  Measurement of lung function in awake 2-4-year-old asthmatic children during methacholine challenge and acute asthma: a comparison of the impulse oscillation technique, the interrupter technique, and transcutaneous measurement of oxygen versus whole-body plethysmography.

Authors:  B Klug; H Bisgaard
Journal:  Pediatr Pulmonol       Date:  1996-05

4.  Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network.

Authors:  J M Drazen; E Israel; H A Boushey; V M Chinchilli; J V Fahy; J E Fish; S C Lazarus; R F Lemanske; R J Martin; S P Peters; C Sorkness; S J Szefler
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

Review 5.  Perspectives in beta 2-agonist therapy: vox clamantis in deserto vel lux in tenebris?

Authors:  E R McFadden
Journal:  J Allergy Clin Immunol       Date:  1995-03       Impact factor: 10.793

6.  Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma.

Authors:  T Haahtela; M Järvinen; T Kava; K Kiviranta; S Koskinen; K Lehtonen; K Nikander; T Persson; K Reinikainen; O Selroos
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

7.  Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial.

Authors:  Elliot Israel; Vernon M Chinchilli; Jean G Ford; Homer A Boushey; Reuben Cherniack; Timothy J Craig; Aaron Deykin; Joanne K Fagan; John V Fahy; James Fish; Monica Kraft; Susan J Kunselman; Stephen C Lazarus; Robert F Lemanske; Stephen B Liggett; Richard J Martin; Nandita Mitra; Stephen P Peters; Eric Silverman; Christine A Sorkness; Stanley J Szefler; Michael E Wechsler; Scott T Weiss; Jeffrey M Drazen
Journal:  Lancet       Date:  2004 Oct 23-29       Impact factor: 79.321

8.  Asthma and wheezing in the first six years of life. The Group Health Medical Associates.

Authors:  F D Martinez; A L Wright; L M Taussig; C J Holberg; M Halonen; W J Morgan
Journal:  N Engl J Med       Date:  1995-01-19       Impact factor: 91.245

9.  Effect of early vs late intervention with inhaled corticosteroids in asthma.

Authors:  O Selroos; A Pietinalho; A B Löfroos; H Riska
Journal:  Chest       Date:  1995-11       Impact factor: 9.410

10.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.

Authors:  A Woolcock; B Lundback; N Ringdal; L A Jacques
Journal:  Am J Respir Crit Care Med       Date:  1996-05       Impact factor: 21.405

View more
  20 in total

1.  The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children.

Authors:  Mohamed S Al-Moamary; Sami A Alhaider; Abdullah A Alangari; Mohammed O Al Ghobain; Mohammed O Zeitouni; Majdy M Idrees; Abdullah F Alanazi; Adel S Al-Harbi; Abdullah A Yousef; Hassan S Alorainy; Mohamed S Al-Hajjaj
Journal:  Ann Thorac Med       Date:  2019 Jan-Mar       Impact factor: 2.219

2.  Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN).

Authors:  Robert D Simari; Lemuel A Moyé; Sonia I Skarlatos; Stephen G Ellis; David X M Zhao; James T Willerson; Timothy D Henry; Carl J Pepine
Journal:  J Cardiovasc Transl Res       Date:  2010-02       Impact factor: 4.132

3.  Discovering Pediatric Asthma Phenotypes on the Basis of Response to Controller Medication Using Machine Learning.

Authors:  Mindy K Ross; Jinsung Yoon; Auke van der Schaar; Mihaela van der Schaar
Journal:  Ann Am Thorac Soc       Date:  2018-01

4.  A Perspective: Division of Lung Diseases at Fifty.

Authors:  Gail G Weinmann; Thomas L Croxton; Neil R Aggarwal; Michael J Twery; James P Kiley
Journal:  Am J Respir Crit Care Med       Date:  2019-12-15       Impact factor: 21.405

5.  P2X7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy.

Authors:  Loren C Denlinger; David M Manthei; Max A Seibold; Kwangmi Ahn; Eugene Bleecker; Homer A Boushey; William J Calhoun; Mario Castro; Vernon M Chinchili; John V Fahy; Greg A Hawkins; Nicolina Icitovic; Elliot Israel; Nizar N Jarjour; Tonya King; Monica Kraft; Stephen C Lazarus; Erik Lehman; Richard J Martin; Deborah A Meyers; Stephen P Peters; Dagna Sheerar; Lei Shi; E Rand Sutherland; Stanley J Szefler; Michael E Wechsler; Christine A Sorkness; Robert F Lemanske
Journal:  Am J Respir Crit Care Med       Date:  2012-11-09       Impact factor: 21.405

Review 6.  Advancing asthma care: the glass is only half full!

Authors:  Stanley J Szefler
Journal:  J Allergy Clin Immunol       Date:  2011-07-27       Impact factor: 10.793

Review 7.  Key observations from the NHLBI Asthma Clinical Research Network.

Authors:  Stanley J Szefler; Vernon M Chinchilli; Elliot Israel; Loren Clark Denlinger; Robert F Lemanske; William Calhoun; Stephen P Peters
Journal:  Thorax       Date:  2012-05       Impact factor: 9.139

8.  Polygenic heritability estimates in pharmacogenetics: focus on asthma and related phenotypes.

Authors:  Michael J McGeachie; Eli A Stahl; Blanca E Himes; Sarah A Pendergrass; John J Lima; Charles G Irvin; Stephen P Peters; Marylyn D Ritchie; Robert M Plenge; Kelan G Tantisira
Journal:  Pharmacogenet Genomics       Date:  2013-06       Impact factor: 2.089

Review 9.  Designing clinical trials to address the needs of childhood and adult asthma: the National Heart, Lung, and Blood Institute's AsthmaNet.

Authors:  E Rand Sutherland; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2014-01       Impact factor: 10.793

10.  Body mass index and phenotype in subjects with mild-to-moderate persistent asthma.

Authors:  E Rand Sutherland; Erik B Lehman; Mihaela Teodorescu; Michael E Wechsler
Journal:  J Allergy Clin Immunol       Date:  2009-06       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.